

**Notice to 340B Covered Entities Regarding Recalculated 340B Ceiling Prices for Merck Products  
(Organon labeler code: 00052) For the Periods 2Q2003-2Q2013**

Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., recently recalculated Average Manufacturer Price and Best Price values previously submitted to the Centers for Medicare and Medicaid Services for certain quarters between 4Q2002 and 3Q2007 for the products listed below. In connection with that recalculation, Merck also recalculated the 340B ceiling prices for the affected products for the associated quarters between 2Q2003 and 1Q2008.

In addition, the recalculation affected the Base AMPs for certain products launched during the recalculation period. For those products, the Base AMPs were changed effective with the 1Q2013 price filing. Accordingly, Merck recalculated the 340B ceiling prices for the affected products for the quarters between 2Q2003 and 2Q2013 to reflect the revised Base AMPs.

Merck will be communicating with and issuing refunds to 340B Covered Entities where our data demonstrates a difference between the original and recalculated 340B ceiling prices paid during impacted quarters by such Covered Entities for the following products:

<b>Product</b>	<b>NDC</b>	<b>Product Description</b>	<b>Impacted Quarters</b>
REMERON <sup>®</sup>	00052-0105	REMERON (MIRTAZAPINE) TABLETS	2Q 2003 through 1Q 2008
REMERON <sup>®</sup>	00052-0106	15MG REMERON SOLTAB (MIRTAZAPINE) ORALLY DISINTEGRATING TABLET	2Q 2003 through 1Q 2008
REMERON <sup>®</sup>	00052-0107	REMERON (MIRTAZAPINE) TABLETS	2Q 2003 through 1Q 2008
REMERON <sup>®</sup>	00052-0108	30MG REMERON SOLTAB (MIRTAZAPINE) ORALLY DISINTEGRATING TABLET	2Q 2003 through 1Q 2008
REMERON <sup>®</sup>	00052-0109	REMERON (MIRTAZAPINE) TABLETS	2Q 2003 through 1Q 2008
REMERON <sup>®</sup>	00052-0110	45MG REMERON SOLTAB (MIRTAZAPINE) ORALLY DISINTEGRATING TABLET	2Q 2003 through 1Q 2008
Desogen <sup>®</sup>	00052-0261	DESOGEN (DESOGESTREL AND ETHINYL ESTRADIOL) TABLETS	2Q 2003 through 1Q 2008
IMPLANON <sup>®</sup>	00052-0272	Implanon 68mg Implant	2Q 2007 through 2Q 2013
NuvaRing <sup>®</sup>	00052-0273	NUVARING (ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING)	2Q 2003 through 2Q 2013
MIRCETTE <sup>®</sup>	00052-0281	MIRCETTE (DESOGESTREL/ETHINYL ESTRADIOL & ETHINYLESTRADIOL)	2Q 2003 through 1Q 2008
Cyclessa <sup>®</sup>	00052-0283	CYCLESSA (DESOGESTREL/ETHINYL ESTRADIOL)	2Q 2003 through 1Q 2008
Ganirelix Acetate	00052-0301	ANTAGON (GANMIRELEX)	4Q 2003 through 2Q

Injection		ACETATE)	2013
FOLLISTIM®	00052-0302	FOLLISTIM/ANATAGON (FOLLISTIM BETA & BANIRELIX ACETATE INJ)	2Q 2003 through 1Q 2005
FOLLISTIM®	00052-0306	FOLLISTIM (FOLLITROPIN BETA FOR INJECTION)	2Q 2003 through 1Q 2005
FOLLISTIM®	00052-0308	FOLLISTIM AQ VIAL 75 IU	2Q 2006 through 2Q 2013
FOLLISTIM®	00052-0309	FOLLISTIM AQ VIAL 150 IU	2Q 2006 through 2Q 2013
FOLLISTIM®	00052-0313	FOLLISTIM AQ CARTRIDGE 300 IU	3Q 2004 through 2Q 2013
Pregnyl®	00052-0315	PREGNYL (CHORIONIC GONADOTROPIN FOR INJECTION USP)	2Q 2003 through 3Q 2006, 3Q 2007, 4Q 2007, 1Q 2008
FOLLISTIM®	00052-0316	FOLLISTIM AQ CARTRIDGE 600 IU	3Q 2004 through 2Q 2013
FOLLISTIM®	00052-0326	Follistim Cartridge 900IU	1Q 2006 through 2Q 2013
NORCURON®	00052-0441	NORCURON (VECURONIUM BROMIDE) FOR INJECTION WITHOUT DILUENT	2Q 2003 through 1Q 2008
SUCCINYLBCHOLINE CHLORIDE	00052-0445	SUCCINYLBCHOLINE CHLORIDE INJECTION, USP (20MG/ML)	3Q 2004 through 1Q 2008
ZEMURON®	00052-0450	ZEMURON (ROCURONIUM BROMIDE) INJECTION	2Q 2003 through 1Q 2008
REVERSOL	00052-0466	REVERSOL (EDROPHONIUM CHLORIDE INJ	2Q 2003 through 1Q 2005
TICE®	00052-0602	TICE BCG	2Q 2003 through 1Q 2008
Deca Durabolin	00052-0697	DECA DURABOLIN(NANDROLON E DECANOATE INJECTION,USP) VIALS	2Q 2003 through 1Q 2005, 1Q 2006 through 1Q 2008
Deca Durabolin	00052-0698	DECA DURABOLIN (NAND	2Q 2003 through 1Q 2005, 3Q 2006 though 1Q 2008
Cortrosyn®	00052-0731	CORTROSYN (COSYNTROPIN) FOR INJECTION	2Q 2003 through 1Q 2005, 4Q 2006 though 1Q 2008

If any 340B Covered Entity that purchased affected product during an impacted quarter, as identified above, believes it may be eligible for a refund, or has questions regarding the refund process, please send an email to [Organon\\_340B\\_Refund@merck.com](mailto:Organon_340B_Refund@merck.com) or submit inquiries via mail, no later than March 31, 2014, to: Organon 340B Refund Coordinator, WP 39-124, PO Box 4, West Point, PA 19486.